INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-964-3720
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
INmune Bio (NASDAQ:INMB) Frequently Asked Questions
What is INmune Bio's stock symbol?
INmune Bio trades on the NASDAQ under the ticker symbol "INMB."
How were INmune Bio's earnings last quarter?
INmune Bio Inc (NASDAQ:INMB) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.16. View INmune Bio's Earnings History.
When is INmune Bio's next earnings date?
What price target have analysts set for INMB?
2 analysts have issued twelve-month price targets for INmune Bio's stock. Their forecasts range from $11.50 to $13.00. On average, they expect INmune Bio's stock price to reach $12.25 in the next year. This suggests a possible upside of 225.8% from the stock's current price. View Analyst Price Targets for INmune Bio.
What is the consensus analysts' recommendation for INmune Bio?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for INmune Bio.
What are Wall Street analysts saying about INmune Bio stock?
Here are some recent quotes from research analysts about INmune Bio stock:
- 1. HC Wainwright analysts commented, "We maintain our Buy rating of INMB and our 12-month price target of $11.50 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from 2030, assuming a 13% discount rate and a 0.5% terminal growth rate. We derive an rNPV of $345M for the products and add in cash and cash equivalents of $9.4M to arrive at a 12-month price target of $11.43 per diluted share, which we round to $11.50." (9/12/2019)
- 2. Maxim Group analysts commented, "INmune Bio reported 2Q19 with operating expenses of ~$2M, partially offset by a $1.5M non-cash charge (waiver of common stock issuable); net loss was ($0.4M). The company ended the period with $9.4M in cash on the balance sheet. In addition, recall that as a result of the $1M grant from the Alzheimer’s foundation and also conducting trials abroad which comes with significant R&D reimbursement, the runway is further extended." (8/14/2019)
Has INmune Bio been receiving favorable news coverage?
Headlines about INMB stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. INmune Bio earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for INmune Bio.
Are investors shorting INmune Bio?
INmune Bio saw a increase in short interest in September. As of September 30th, there was short interest totalling 26,700 shares, an increase of 21.4% from the August 30th total of 22,000 shares. Based on an average daily trading volume, of 29,100 shares, the short-interest ratio is currently 0.9 days. Currently, 0.7% of the company's shares are sold short. View INmune Bio's Current Options Chain.
Who are some of INmune Bio's key competitors?
Some companies that are related to INmune Bio include Oncobiologics (ONS), X4 Pharmaceuticals (XFOR), Axcella Health (AXLA), Nantkwest (NK), Acorda Therapeutics (ACOR), Windtree Therapeutics (WINT), Novavax (NVAX), Aptose Biosciences (APTO), Gamida Cell (GMDA), Jounce Therapeutics (JNCE), Adaptimmune Therapeutics (ADAP), Allena Pharmaceuticals (ALNA), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC) and Polarityte (PTE).
What other stocks do shareholders of INmune Bio own?
Who are INmune Bio's key executives?
INmune Bio's management team includes the folowing people:
- Dr. Raymond Joseph Tesi, Co-Founder, Pres, CEO & Director (Age 63)
- Mr. David J. Moss M.B.A., CFO, Treasurer & Sec. (Age 49)
- Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Chief Scientific Officer (Age 56)
How do I buy shares of INmune Bio?
Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is INmune Bio's stock price today?
One share of INMB stock can currently be purchased for approximately $3.76.
How big of a company is INmune Bio?
What is INmune Bio's official website?
How can I contact INmune Bio?
INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at 858-964-3720 or via email at [email protected]
MarketBeat Community Rating for INmune Bio (NASDAQ INMB)
MarketBeat's community ratings are surveys of what our community members think about INmune Bio and other stocks. Vote "Outperform" if you believe INMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
